27
October

08:00 AM BST

Clinical Operations

Name: Clinical Operations & Clinical Trial Supply Chain Strategy Meeting Europe 2026
Start: 2026-02-27T08:00
End: 2026-10-27T18:00
Location: Crowne Plaza, London Docklands

&

Clinical Trial Supply Chain

Strategy Meeting Europe 2026

Effective integration of patient outcomes in clinical trial design, Overcoming under-enrollment of ethnic minorities, Employing RBQM and deep learning to your Trial knowledge.

Crowne Plaza London Docklands

Our Event Starts In

–
days

–
hours

–
minutes

–
seconds

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Clinical Operations Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s Clinical Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Clinical Operations professionals from across Europe, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across Europe, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We've partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Our Past Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Clinical Operations strategy meeting.

Aditya Tallapragada

President AKT Health Inc.

Aditya Tallapragada is the President of AKT Health, bringing over 18+ years of global, multilingual experience across the HealthTech, FinTech, and Life Sciences sectors. As a serial entrepreneur and strategic advisor, he blends deep industry insight with a passion for technology-driven transformation to deliver sustainable, patient-centric solutions. He is known for his leadership in Digital health innovation, offering strategic guidance to startups, enterprises, and blockchain ventures. Aditya’s focus lies in leveraging AI, ML, and blockchain to drive operational efficiency, enhance decision-making, and generate tangible outcomes across healthcare and finance. A recognized speaker and investor, he is also the holder of a patent for an Innovative Information Management System, a breakthrough that simplifies healthcare data workflows and strengthens patient data management. This innovation highlights his dedication to solving realworld challenges with practical, scalable technology. His cross-sector expertise spans market access strategy, global regulatory affairs, econometric modeling, commercial development, and digital transformation, making him a sought-after thought leader in the future of digital health and decentralized ecosystems.

Arijit Patra

Senior Principal Scientist UCB

Dr. Arijit Patra is a Senior Principal Scientist at UCB Biopharma UK and an honorary senior lecturer (associate professor) at the University of Glasgow. He holds a PhD in machine learning for healthcare imaging from the University of Oxford, where he was a Rhodes Scholar (India & Exeter, 2016). Prior to that, he completed a dual degree in mechanical engineering from the Indian Institute of Technology (IIT) at Kharagpur, India, as a Honda Young Engineer & Scientist awardee. He has also been associated with AstraZeneca, Shell, Microsoft Research, and CSIR-South Africa at various points in his career and has been actively involved in the AI4SG (AI for Social Good) community. He has authored several publications around machine learning and medical imaging and is a reviewer for multiple peer-reviewed venues such as NeurIPS, ICML, MICCAI, and several journals. Arijit has been appointed as a Rising Leaders fellow of the Aspen Institute UK, as an International Strategy Forum fellow in 2024, and more recently as an Aspen Ideas Healthcare fellow for 2025.

Bryony Harrop

Vice President, Clinical Development Artios Pharma Ltd

Charmaine O’Neill

Vice President, Clinical Operations Vantage Biosciences & Axovia Therapeutics

Claire Herholdt

Vice President, Clinical Operations Levicept Ltd

David Gillen

Chief Medical Officer Norgine

David is the Chief Medical Officer at Norgine and has been in post since May 2022. David qualified in Medicine, Physiology and Clinical Pharmacology from St. Mary’s Hospital (Imperial College of Science, Technology and Medicine) in 1992. He retained this interest in Pharmaceutical Medicine during his postgraduate training in Cardiology and General Medicine and joined Pfizer Global Research and Development in Sandwich in 1999. After leaving Pfizer David held the role of Head of International Medical Affairs for Gilead Sciences. In 2011 he then moved to work at Celgene where he was Head of Drug Safety and Risk Management for EMEA / APAC for Celgene Ltd. In addition David acted as the QPPV for Celgene’s Pharmacovigilance System in Europe. In 2016 David moved to become Vice President of International Medical Affairs atVertex. In 2019, he was given additional responsibility supervising the whole International Global Development and Medical Affairs function for Vertex. In 2022 David became CMO of Norgine based in London. David has served on the Innovation sub- committee of the ABPI (Initiating the ABPI Real – World data project), represented Industry on the NICE Appeal Panel and was a member of the important RCP working party looking at the relationship between Industry, Academic Medicine and the NHS. David is a visiting Lecturer at Queens University Belfast and Kings College London.

Dr. Annette Janus

Chief Medical Officer Axoltis Pharma

Dr. Loredana Pătru

Regional Medical Director Romania & Medical Lead Trial Optimization - ARENSIA

Dr. Nermeen Varawalla

Chief Medical Officer Scancell Ltd

Dr. Nermeen Varawalla is a business leader in the healthcare & life sciences sectors with expertise in drug development and presently serves as Chief Medical Officer at Scancell Ltd, leading the clinical development of its cancer immunotherapies. Nermeen completed her medical training at the University of Mumbai before receiving a Rhodes Fellowship for her doctorate at Oxford University, following which she worked as an NHS obstetrician and gynecologist. After an MBA at INSEAD, Nermeen transitioned to business by joining Accenture’s Strategy Consulting Practice. Recognizing the opportunity to conduct global clinical trials in India, Nermeen founded a pioneering business, which she sold to PRA Health Sciences (now ICON plc), and proceeded to hold leadership roles in the contract research business. Notably, Nermeen raised private equity financing to build ECCRO, which she exited to join the Intas Pharmaceutical Group. Following this transition, Nermeen has held leadership roles at several biopharmaceutical and medical technology companies, including BTG International plc. until its acquisition by Boston Scientific Corporation, Atlantic Healthcare, and Relief Therapeutics. In addition, she has served as a trustee board member for the Malaria Consortium. Nermeen also serves as Chair of Atorvia Health Technologies with a lead asset for kidney failure, Board Member of the Oxford India Centre at the University of Oxford, and on the Board of Governors at the University of Hertfordshire to provide guidance for the setup of its new medical school. Further, Nermeen is President of the UK INSEAD Alumni Association and the Alumni Association of Somerville College, University of Oxford.

Dr. Rania Al Shami

Chief Business and Strategy Officer PDC - CRO

Farrell Healion

Former Head, Emerging Technology - Senior Director, Global Clinical Solutions AstraZeneca

Kate Lindsell

Vice President, Clinical Operations Zura Bio

Jane Twitchen

Executive Director, Head, Clinical Trial Accelerator Unit Biogen

Jane Twitchen graduated with a BSc in Medical Physics from the University of Exeter, UK and commenced her career with Covance, supporting a number of trials investigating radioisotope image optimisation. Having developed a keen interest in processes and systems, she then joined SAS, where she worked in the Alliances team collaborating with partners such as PWC, McKinsey and Accenture to define and implement solutions for pharmaceutical clients. During her tenure with SAS, Jane was also sponsored to complete her MBA. She proceeded to a number of software and service providers prior to joining Biogen in 2013, initially joining the Global Regulatory Affairs Quality and Operations team and moving to Global Clinical Operations in 2015. In her current role, Jane is Executive Director, Head of Biogen’s Clinical Trial Accelerator Unit and is responsible for delivery of Biogen’s goals for accelerated study start-up cycle time, in addition to embedding innovative operational delivery through the use of technology.

Lucy Moore

Executive Director, Clinical Data Projects, Clinical Data and Insights AstraZeneca

Mohamed Mostafa

Chief Executive Officer PDC - CRO

Paullette Azar-Tannous

Chief Executive Officer Sonic Clinical Trials

Paullette has over 30 years of leadership in global central laboratory services supporting pharmaceutical and biotech industries across Asia Pacific, Europe, and the US. She leads a highly specialized global team focused on delivering integrated clinical trial solutions with a strong emphasis on operational excellence, innovation, and collaboration. Her areas of expertise span laboratory and quality management systems, systems development, corporate training and development, risk and crisis management, stakeholder engagement, ESG leadership, and corporate and commercial strategy. Paullette has successfully established start-up operations in Australia, Singapore, Belgium, and the US; led large-scale transformation initiatives; shaped operational frameworks; mentored emerging leaders; and fostered collaboration of diverse teams within complex, global organizations. Paullette holds a Bachelor of Biomedical Sciences, a Master of Business Management, and is a recent graduate of the Australian Institute of Company Directors course.

Peter Eley

Manager Clinical Supply Chain Kiniksa Pharmaceuticals

Simon Collins

Executive Director, Head of Oncology Clinical Operations Jazz Pharmaceuticals

First name	Last name	Job title	Company name	Photo URL	Bio Position
Aditya	Tallapragada	President	AKT Health Inc.	https://proventainternational.com/wp-content/uploads/2025/08/Aditya-Tallapragada.jpg	Aditya Tallapragada is the President of AKT Health, bringing over 18+ years of global, multilingual experience across the HealthTech, FinTech, and Life Sciences sectors. As a serial entrepreneur and strategic advisor, he blends deep industry insight with a passion for technology-driven transformation to deliver sustainable, patient-centric solutions. He is known for his leadership in Digital health innovation, offering strategic guidance to startups, enterprises, and blockchain ventures. Aditya’s focus lies in leveraging AI, ML, and blockchain to drive operational efficiency, enhance decision-making, and generate tangible outcomes across healthcare and finance. A recognized speaker and investor, he is also the holder of a patent for an Innovative Information Management System, a breakthrough that simplifies healthcare data workflows and strengthens patient data management. This innovation highlights his dedication to solving realworld challenges with practical, scalable technology. His cross-sector expertise spans market access strategy, global regulatory affairs, econometric modeling, commercial development, and digital transformation, making him a sought-after thought leader in the future of digital health and decentralized ecosystems.
Arijit	Patra	Senior Principal Scientist	UCB	https://proventainternational.com/wp-content/uploads/2025/09/Arijit-Patra.jpg	Dr. Arijit Patra is a Senior Principal Scientist at UCB Biopharma UK and an honorary senior lecturer (associate professor) at the University of Glasgow. He holds a PhD in machine learning for healthcare imaging from the University of Oxford, where he was a Rhodes Scholar (India & Exeter, 2016). Prior to that, he completed a dual degree in mechanical engineering from the Indian Institute of Technology (IIT) at Kharagpur, India, as a Honda Young Engineer & Scientist awardee. He has also been associated with AstraZeneca, Shell, Microsoft Research, and CSIR-South Africa at various points in his career and has been actively involved in the AI4SG (AI for Social Good) community. He has authored several publications around machine learning and medical imaging and is a reviewer for multiple peer-reviewed venues such as NeurIPS, ICML, MICCAI, and several journals. Arijit has been appointed as a Rising Leaders fellow of the Aspen Institute UK, as an International Strategy Forum fellow in 2024, and more recently as an Aspen Ideas Healthcare fellow for 2025.
Bryony	Harrop	Vice President, Clinical Development	Artios Pharma Ltd	https://proventainternational.com/wp-content/uploads/2025/09/Bryony-Harrop.jpg	Bryony has served as Vice President of Clinical Development at Artios Pharma since 2020 and has taken 3 oncology DNA Damage Response projects into the clinic in that time. Bryony is a seasoned pharmaceutical industry professional with over 25 years of experience through all stages of drug development in cutting-edge oncology clinical trials across a broad range of malignancies. She was previously Oncology Delivery Director at AstraZeneca, where she held various leadership positions in the Early Clinical Development, Global Project Management, and Global Medical Affairs units over a period of fifteen years. Before AstraZeneca, Bryony worked at Eisai and at contract research organizations such as MDS Harris and Chiltern International Limited, and in the NHS at Northampton Community Healthcare Trust. Bryony holds a BSc in Biochemistry and Biological Chemistry from the University of Nottingham.
Charmaine	O’Neill	Vice President, Clinical Operations	Vantage Biosciences & Axovia Therapeutics	https://proventainternational.com/wp-content/uploads/2025/07/Charmaine-ONeill.jpg	Charmaine O’Neill brings over 30 years of diverse experience in Research and Development, currently supporting Axovia Therapeutics and Vantage Biosciences. She was most recently with Gyroscope Therapeutics, a Novartis company, and has held senior roles across pharma and biotech, including GSK, Aimmune Therapeutics, DSPE, PPD, Syneos, and hVivo. Charmaine has led global Phase I–III clinical programs to registration across multiple therapeutic areas, including ophthalmology, virology, diabetes, rare diseases, food allergy, and oncology. She holds BSc (Hons) degrees in Pharmacology and Psychology and is recognized for driving operational excellence in clinical trial delivery across early and late development.
Claire	Herholdt	Vice President, Clinical Operations	Levicept Ltd	https://proventainternational.com/wp-content/uploads/2025/06/Claire-Herholdt.jpg	Claire Herholdt has been in clinical operations for 30 years and has worked in big pharma as well as small biotech, across all phases of drug development, and with internal teams and various outsourcing models with large and small vendors.
David	Gillen	Chief Medical Officer	Norgine	https://proventainternational.com/wp-content/uploads/2025/06/David-Gillen-1.jpg	David is the Chief Medical Officer at Norgine and has been in post since May 2022. David qualified in Medicine, Physiology and Clinical Pharmacology from St. Mary’s Hospital (Imperial College of Science, Technology and Medicine) in 1992. He retained this interest in Pharmaceutical Medicine during his postgraduate training in Cardiology and General Medicine and joined Pfizer Global Research and Development in Sandwich in 1999. After leaving Pfizer David held the role of Head of International Medical Affairs for Gilead Sciences. In 2011 he then moved to work at Celgene where he was Head of Drug Safety and Risk Management for EMEA / APAC for Celgene Ltd. In addition David acted as the QPPV for Celgene’s Pharmacovigilance System in Europe. In 2016 David moved to become Vice President of International Medical Affairs atVertex. In 2019, he was given additional responsibility supervising the whole International Global Development and Medical Affairs function for Vertex. In 2022 David became CMO of Norgine based in London. David has served on the Innovation sub- committee of the ABPI (Initiating the ABPI Real – World data project), represented Industry on the NICE Appeal Panel and was a member of the important RCP working party looking at the relationship between Industry, Academic Medicine and the NHS. David is a visiting Lecturer at Queens University Belfast and Kings College London.
Dr.	Annette Janus	Chief Medical Officer	Axoltis Pharma	https://proventainternational.com/wp-content/uploads/2025/09/Annette-Janus.jpg
Dr.	Loredana Pătru	Regional Medical Director Romania & Medical Lead	Trial Optimization - ARENSIA	https://proventainternational.com/wp-content/uploads/2025/09/Dr-Loredana-Patru.jpg	Loredana Pătru, a medical doctor specialized in Clinical Pharmacology, with more than 15 years at ARENSIA, where she now serves both as Regional Medical Director for Romania and as Medical Lead for Trial Optimization. Her focus is on ensuring scientific excellence and operational efficiency across multiple therapeutic areas and medical support for trial optimization in close collaboration with sponsors and external partners.
Dr.	Nermeen Varawalla	Chief Medical Officer	Scancell Ltd	https://proventainternational.com/wp-content/uploads/2025/04/Nermeen-Varawalla.jpg	Dr. Nermeen Varawalla is a business leader in the healthcare & life sciences sectors with expertise in drug development and presently serves as Chief Medical Officer at Scancell Ltd, leading the clinical development of its cancer immunotherapies. Nermeen completed her medical training at the University of Mumbai before receiving a Rhodes Fellowship for her doctorate at Oxford University, following which she worked as an NHS obstetrician and gynecologist. After an MBA at INSEAD, Nermeen transitioned to business by joining Accenture’s Strategy Consulting Practice. Recognizing the opportunity to conduct global clinical trials in India, Nermeen founded a pioneering business, which she sold to PRA Health Sciences (now ICON plc), and proceeded to hold leadership roles in the contract research business. Notably, Nermeen raised private equity financing to build ECCRO, which she exited to join the Intas Pharmaceutical Group. Following this transition, Nermeen has held leadership roles at several biopharmaceutical and medical technology companies, including BTG International plc. until its acquisition by Boston Scientific Corporation, Atlantic Healthcare, and Relief Therapeutics. In addition, she has served as a trustee board member for the Malaria Consortium. Nermeen also serves as Chair of Atorvia Health Technologies with a lead asset for kidney failure, Board Member of the Oxford India Centre at the University of Oxford, and on the Board of Governors at the University of Hertfordshire to provide guidance for the setup of its new medical school. Further, Nermeen is President of the UK INSEAD Alumni Association and the Alumni Association of Somerville College, University of Oxford.
Dr.	Rania Al	Chief Business and Strategy Officer	PDC - CRO	https://proventainternational.com/wp-content/uploads/2025/07/Rania-Alshami.jpg	Dr. Rania Al Shami is the Chief Business and Strategy Officer at PDC-CRO, leading business development and strategic initiatives across the Middle East and Africa. With nearly 20 years of experience, she has been a driving force in strengthening the region’s clinical research infrastructure, advancing global partnerships, and shaping the pharmaceutical, biotech, and healthcare landscapes across MENA.
Farrell	Healion	Former Head, Emerging Technology - Senior Director, Global Clinical Solutions	AstraZeneca	https://proventainternational.com/wp-content/uploads/2025/06/Farrell-Healion.jpg
Kate	Lindsell	Vice President, Clinical Operations	Zura Bio	https://proventainternational.com/wp-content/uploads/2025/09/Kate-Lindsell-1.jpg	Kate Lindsell, PhD, is Vice President of Clinical Operations at Zura Bio Limited (Nasdaq: ZURA), where she leads trial execution across global clinical programs. With over 20 years of experience in clinical development, portfolio management, and operational leadership, Kate’s career spans pharma, biotech, and CROs and includes senior roles at Syneos Health, hVIVO, and the UK Government’s Vaccines Taskforce. Kate holds a PhD in Virology from University College London and a BSc in Applied Biology from the University of Wales. Passionate about clinical research, Kate is known for her strategic mindset and collaborative style, driving cross-functional collaboration and delivering complex trials with precision and impact.
Jane	Twitchen	Executive Director, Head, Clinical Trial Accelerator Unit	Biogen	https://proventainternational.com/wp-content/uploads/2022/03/Jane-Twitchen.jpg	Jane Twitchen graduated with a BSc in Medical Physics from the University of Exeter, UK and commenced her career with Covance, supporting a number of trials investigating radioisotope image optimisation. Having developed a keen interest in processes and systems, she then joined SAS, where she worked in the Alliances team collaborating with partners such as PWC, McKinsey and Accenture to define and implement solutions for pharmaceutical clients. During her tenure with SAS, Jane was also sponsored to complete her MBA. She proceeded to a number of software and service providers prior to joining Biogen in 2013, initially joining the Global Regulatory Affairs Quality and Operations team and moving to Global Clinical Operations in 2015. In her current role, Jane is Executive Director, Head of Biogen’s Clinical Trial Accelerator Unit and is responsible for delivery of Biogen’s goals for accelerated study start-up cycle time, in addition to embedding innovative operational delivery through the use of technology.
Lucy	Moore	Executive Director, Clinical Data Projects, Clinical Data and Insights	AstraZeneca	https://proventainternational.com/wp-content/uploads/2025/05/Lucy-Moore.jpg	As an Executive Director at AstraZeneca, Lucy leads a comprehensive transformation programme to revolutionise patient data automation, processes, and IT infrastructure across clinical operations, medical oversight, and biometrics. With over twenty years of experience in clinical trial operations and biometrics, she is passionate about using digital advances to transform clinical trial delivery. Lucy initially gained vast clinical trial experience as a study and project data manager and then broadened her knowledge with differing operational roles, including setting up delivery models, alliance management, and business operations and planning.
Mohamed	Mostafa	Chief Executive Officer	PDC - CRO	https://proventainternational.com/wp-content/uploads/2025/07/Mohamed-Mostafa.jpg	Mohamed Mostafa is the Chief Executive Officer and Board Member of PDC-CRO, leading a workforce that supports pharmaceutical, biotech, and research institutions in clinical development and transformational research. With over two decades of experience, he has dedicated his career to expanding research capabilities and infrastructure, improving patient access to innovative treatments, and driving strategic initiatives in partnership with global stakeholders and regulatory agencies.
Paullette	Azar-Tannous	Chief Executive Officer	Sonic Clinical Trials	https://proventainternational.com/wp-content/uploads/2025/07/Paullette-Azar.jpg	Paullette has over 30 years of leadership in global central laboratory services supporting pharmaceutical and biotech industries across Asia Pacific, Europe, and the US. She leads a highly specialized global team focused on delivering integrated clinical trial solutions with a strong emphasis on operational excellence, innovation, and collaboration. Her areas of expertise span laboratory and quality management systems, systems development, corporate training and development, risk and crisis management, stakeholder engagement, ESG leadership, and corporate and commercial strategy. Paullette has successfully established start-up operations in Australia, Singapore, Belgium, and the US; led large-scale transformation initiatives; shaped operational frameworks; mentored emerging leaders; and fostered collaboration of diverse teams within complex, global organizations. Paullette holds a Bachelor of Biomedical Sciences, a Master of Business Management, and is a recent graduate of the Australian Institute of Company Directors course.
Peter	Eley	Manager Clinical Supply Chain	Kiniksa Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2025/10/Peter-Eley.jpg
Simon	Collins	Executive Director, Head of Oncology Clinical Operations	Jazz Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2025/07/Simon-Collins.jpg	Simon Collins has over 25 years of experience in research and development, gained from having worked at CROs and several large and mid-sized biopharmaceutical companies. Simon is currently the Head of Oncology Clinical Operations at Jazz Pharmaceuticals but also has experience leading clinical programs focused on postmenopausal osteoporosis, migraine, and inflammatory bowel disease. Additionally, Simon has held leadership roles overseeing clinical quality assurance, transformation management, resource capacity management, and business process management functions. Simon has a passion for driving operational excellence, fostering cross-functional collaboration, and accelerating innovative therapies to patients. Simon has a degree in biological sciences (Leicester) and a PhD in animal physiology (Exeter).

Aditya Tallapragada, Arijit Patra, Bryony Harrop, Charmaine O’Neill, Claire Herholdt, David Gillen, Dr. Annette Janus, Dr. Loredana Pătru, Dr. Nermeen Varawalla, Dr. Rania Al Shami, Farrell Healion, Kate Lindsell, Jane Twitchen, Lucy Moore, Mohamed Mostafa, Paullette Azar-Tannous, Peter Eley, Simon Collins

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

Clinical Trials Europe

Clinical Operations & Clinical Trial Supply Chain Strategy Meeting Europe 2025

&

Strategy Meeting Europe 2026

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Crowne Plaza London Docklands

Fresh Clinical Operations Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Our Past Facilitators

Aditya Tallapragada

Arijit Patra

Bryony Harrop

Charmaine O’Neill

Claire Herholdt

David Gillen

Dr. Annette Janus

Dr. Loredana Pătru

Dr. Nermeen Varawalla

Dr. Rania Al Shami

Farrell Healion

Kate Lindsell

Jane Twitchen

Lucy Moore

Mohamed Mostafa

Paullette Azar-Tannous

Peter Eley

Simon Collins

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

Breakfast & Registration

Opening Keynote Presentation

Revolutionizing Clinical Trials: Trends Shaping the Next Era of Research

Roundtable

Roundtable Tracks

Refreshment Break

Networking / 1-1 Meetings

Roundtable (Solution)

Roundtable ( Pharma/Biotech )

Sponsor

AKT HEALTH

PDC - CRO

SONIC CLINICAL TRIALS

Roundtable ( Pharma/Biotech )

Roundtable ( Pharma/Biotech )

Networking Lunch

Networking / 1-1 Meetings

Afternoon Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Afternoon Refreshment Break

Panel Discussion

Harnessing AI in Clinical Trials: The Tech Frontier of 2025

Drinks & Canapes Reception

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Our Sponsors

Co-Host Sponsors

Our Partnering Sponsors

Key Opinion Leader

Become an official strategy meeting partner

Explore Highlight From The Past Events

Testimonials

Hotel & Venue

Crowne Plaza London Docklands

Here To Help

Want to find out more?

Crowne Plaza London Docklands